文献速递冠心病心律失常

房颤合并急性冠脉综合征或择期PCI患者的抗栓治疗:AUGUSTUS试验洞察

Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
PubMed 文献 · Circulation · 2019-09-26

AUGUSTUS试验的预设亚组分析比较了房颤合并ACS(药物治疗或PCI)或择期PCI患者中阿哌沙班 vs 维生素K拮抗剂、阿司匹林 vs 安慰剂的抗栓策略。结果显示,阿哌沙班较维生素K拮抗剂降低大出血或临床相关非大出血,且不增加死亡和缺血事件;阿司匹林较安慰剂增加出血。

要点

  • 阿哌沙班联合P2Y12抑制剂不联用阿司匹林,在三个亚组中均提供更优安全性和相似疗效。
  • 阿哌沙班较维生素K拮抗剂降低ISTH大出血或临床相关非大出血,ACS药物治疗组HR 0.44。
  • 阿司匹林较安慰剂增加出血风险,ACS-PCI组HR 2.02,择期PCI组HR 1.91。

核心结论

  • 对于房颤合并ACS(无论药物或PCI治疗)或择期PCI患者,阿哌沙班加P2Y12抑制剂而不联用阿司匹林的方案,较含维生素K拮抗剂、阿司匹林或两者兼有的方案,安全更优且疗效相似。

研究设计与样本

  • AUGUSTUS试验为2×2析因设计,纳入4614例房颤合并ACS或接受PCI且使用P2Y12抑制剂的患者,比较阿哌沙班 vs 维生素K拮抗剂和安慰剂 vs 阿司匹林。
  • 预设亚组包括ACS药物治疗1097例(23.9%)、ACS接受PCI 1714例(37.3%)和择期PCI 1784例(38.8%)。

主要发现

  • 阿哌沙班 vs 维生素K拮抗剂降低ISTH大出血或临床相关非大出血:ACS药物治疗组HR 0.44(95%CI 0.28-0.68),ACS-PCI组HR 0.68(95%CI 0.52-0.89),择期PCI组HR 0.82(95%CI 0.64-1.04),交互P=0.052。
  • 阿哌沙班 vs 维生素K拮抗剂对死亡或住院的影响:ACS药物治疗组HR 0.71(95%CI 0.54-0.92),ACS-PCI组HR 0.88(95%CI 0.74-1.06),择期PCI组HR 0.87(95%CI 0.72-1.04),交互P=0.345。
  • 阿司匹林 vs 安慰剂增加出血:ACS药物治疗组HR 1.49(95%CI 0.98-2.26),ACS-PCI组HR 2.02(95%CI 1.53-2.67),择期PCI组HR 1.91(95%CI 1.48-2.47),交互P=0.479。

临床怎么用

  • 房颤合并ACS或接受PCI的患者,可考虑阿哌沙班加P2Y12抑制剂而不联用阿司匹林,以降低出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective PCI. METHODS: Using a 2×2 factorial design, we compared apixaban with vitamin K antagonists and aspirin with placebo in patients with atrial fibrillation who had ACS or were undergoing PCI and were receiving a P2Y12 inhibitor. We explored bleeding, death and hospitalization, as well as death and ischemic events, by antithrombotic strategy in 3 prespecified subgroups: patients with ACS treated medically, patients with ACS treated with PCI, and those undergoing elective PCI. RESULTS: Of 4614 patients enrolled, 1097 (23.9%) had ACS treated medically, 1714 (37.3%) had ACS treated with PCI, and 1784 (38.8%) had elective PCI. Apixaban compared with vitamin K antagonist reduced International Society on Thrombosis and Haemostasis major or clinically relevant nonmajor bleeding in patients with ACS treated medically (hazard ratio [HR], 0.44 [95% CI, 0.28-0.68]), patients with ACS treated with PCI (HR, 0.68 [95% CI, 0.52-0.89]), and patients undergoing elective PCI (HR, 0.82 [95% CI, 0.64-1.04]; Pinteraction=0.052) and reduced death or hospitalization in the ACS treated medically (HR, 0.71 [95% CI, 0.54-0.92]), ACS treated with PCI (HR, 0.88 [95% CI, 0.74-1.06]), and elective PCI (HR, 0.87 [95% CI, 0.72-1.04]; Pinteraction=0.345) groups. Compared with vitamin K antagonists, apixaban resulted in a similar effect on death and ischemic events in the ACS treated medically, ACS treated with PCI, and elective PCI groups (Pinteraction=0.356). Aspirin had a higher rate of bleeding than did placebo in patients with ACS treated medically (HR, 1.49 [95% CI, 0.98-2.26]), those with ACS treated with PCI (HR, 2.02 [95% CI, 1.53-2.67]), and those undergoing elective PCI (HR, 1.91 [95% CI, 1.48-2.47]; Pinteraction=0.479). For the same comparison, there was no difference in outcomes among the 3 groups for the composite of death or hospitalization (Pinteraction=0.787) and death and ischemic events (Pinteraction=0.710). CONCLUSIONS: An antithrombotic regimen consisting of apixaban and a P2Y12 inhibitor without aspirin provides superior safety and similar efficacy in patients with atrial fibrillation who have ACS, whether managed medically or with PCI, and those undergoing elective PCI compared with regimens that include vitamin K antagonists, aspirin, or both. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02415400.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Windecker S, Lopes RD, Massaro T, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. Circulation. 2019. PMID: 31557056. doi:10.1161/CIRCULATIONAHA.119.043308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。